Prospective, non-intervetional, sigle centre clinical trial of leuprorelin combination with exemestane in the treatment of premature menopause metastatic breast caner

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003673

Enrollment

Unknown

Registered

2013-07-12

Start date

2013-10-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

one group:leuprorelin combination with exemestane

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. the patients be eligible for treatment with Enantone combination with AI; 2. first or secondary endocrine therapy; 3. ECOG 02; 4. Recurrent or metastatic breast cancer with histologically/cellular and imaging con?rmed; 5. ER/PR positive; 6. Premenopausal or perimenopausal women; 7. at least one measurable lesions; 8. Expected lifetime>=3months; 9. plenty of organ fuction; 10. Informed consent was required.

Exclusion criteria

Exclusion criteria: 1. attending other studies; 2. Pregnant or lactating women ; 3. sensitive to the drugs; 4. Symptomatic patients with brain metastasis; 5. CNS metastasis or mental patients; 6. treatment with the drugs before enrollment; 7. impaired live and adrenal fuction; 8. protocal deviation; 9. exclude by invesgator.

Design outcomes

Primary

Measure	Time frame
progression-free survival;	—

Secondary

Measure	Time frame
clinical efficacy rate;ORR;	—

Countries

China

Contacts

Public ContactLijun Di

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute

dilijun2012@163.com+86 13501371136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026